Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

N/A

1(14.3%)

Early Phase 1

1(14.3%)

7Total

Phase 1(3)

Phase 2(2)

N/A(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07492316Phase 1Recruiting

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Role: collaborator

NCT04573140Phase 1Recruiting

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

Role: collaborator

NCT06861244Phase 2Recruiting

Embryonal Tumor With Multilayered Rosettes

Role: collaborator

NCT07226453Phase 2Not Yet Recruiting

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

Role: collaborator

NCT05057702Not ApplicableRecruiting

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Role: collaborator

NCT03893487Early Phase 1Active Not Recruiting

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Role: collaborator

NCT04323046Phase 1Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Role: collaborator

All 7 trials loaded